Award Number: W81XWH-08-1-0042

TITLE: PTEN Loss Antagonizes Calcitriol-mediated Growth Inhibition in Prostate Epithelial Cells

PRINCIPAL INVESTIGATOR: Linara S. Axanova, M.S.

CONTRACTING ORGANIZATION: Wake Forest University Health Sciences
Winston Salem, North Carolina 27157-0001

REPORT DATE: May 2010

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT:

X Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
PTEN Loss Antagonizes Calcitriol-mediated Growth Inhibition in Prostate Epithelial Cells

AUTHOR(S)
Linara S. Axanova

PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)
Wake Forest University Health Sciences
Winston Salem, North Carolina 27157-0001

SPONSOR/_MONITOR'S ACRONYM(S)
U. S. Army Medical Research and Material Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION / AVAILABILITY STATEMENT
Approved for public release; distribution unlimited

ABSTRACT
BACKGROUND: 1-alpha, 25-dihydroxy vitamin D3 (1,25(OH)₂D₃) inhibits proliferation of multiple cancer cell types including prostate cells and upregulates p21 and/or p27, while loss of Pten and PI3K/AKT activation stimulates survival and downregulates p21 and p27. We hypothesized that inhibition of the PI3K/AKT pathway synergizes with the antiproliferative signaling of 1,25(OH)₂D₃. METHODS: Viability, cell cycle and senescence of cells were evaluated upon combinational treatment with 1,25(OH)₂D₃ and pharmacological PI3K/AKT inhibitors. RESULTS: Pharmacological inhibitors of PI3K or Akt and 1,25(OH)₂D₃ synergistically inhibited growth of DU145, LNCaP, primary human prostate cancer cell strains and Pten null mouse prostatic epithelial cells (MPEC). A novel mechanism for antiproliferative effects of 1,25(OH)₂D₃ in prostate cells, induction of senescence, was discovered. Combination of 1,25(OH)₂D₃ and AKT inhibitor cooperated to induce G₁ arrest, senescence, and p21 levels in prostate cancer cells. As AKT is commonly activated by PTEN loss, we evaluated the role of Pten in responsiveness to 1,25(OH)₂D₃ by shRNA knockdown and by in vitro knockout of Pten. MPEC that lost Pten expression remained sensitive to the antiproliferative action of 1,25(OH)₂D₃, and showed higher degree of synergism between AKT inhibitor and 1,25(OH)₂D₃ compared to Pten-expressing counterparts. CONCLUSIONS: These findings provide the rationale for the development of therapies utilizing 1,25(OH)₂D₃ or its analogs combined with inhibition of PI3K/AKT for the treatment of prostate cancer.

SUBJECT TERMS
Vitamin D₃, AKT inhibition, synergism, prostate cancer
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>4</td>
</tr>
<tr>
<td>Body</td>
<td>6</td>
</tr>
<tr>
<td>Key Research Accomplishments</td>
<td>13</td>
</tr>
<tr>
<td>Reportable Outcomes</td>
<td>13</td>
</tr>
<tr>
<td>Conclusion</td>
<td>14</td>
</tr>
<tr>
<td>References</td>
<td>15</td>
</tr>
<tr>
<td>Appendices</td>
<td>17</td>
</tr>
<tr>
<td>Article published in Prostate Journal (in press)</td>
<td>17</td>
</tr>
</tbody>
</table>
Introduction

Prostate cancer (CaP) is the most commonly diagnosed cancer and the second most common cause of cancer death in American men \(^1\). It has been suggested that the development of clinical prostate cancer may be associated with vitamin D\(_3\) deficiency \(^2,3\).

Vitamin D is a hormone that can be obtained from the diet or produced endogenously by a series of reactions that culminates in the most active metabolite of vitamin D, \(1\alpha, 25(\text{OH})_2\text{D}_3\) (1,25(OH)\(_2\)D\(_3\)). The classical targets of 1,25(OH)\(_2\)D\(_3\) are kidney, intestine and bone where it maintains serum calcium levels within narrow range required for several vital functions such as bone mineralization, immune and neuromuscular function, signal transduction and blood coagulation \(^4\). Hormonally active 1,25(OH)\(_2\)D\(_3\) is synthesized from vitamin D\(_3\) (also called cholecalciferol). Vitamin D\(_3\) can be obtained from dietary sources such as milk and fish oils or can be synthesized endogenously. During endogenous synthesis, UVB rays provide the energy required to convert 7-dehydrocholesterol present in the skin to vitamin D\(_3\). Vitamin D\(_3\) from the skin is first transported to the liver. In the liver, a mitochondrial enzyme 25-hydroxylase hydroxylates the C25 position of vitamin D\(_3\) to generate 25(OH)D3 \(^5\). 25(OH)D3 is then transported to kidney where hydroxylation at the C1 position by an enzyme 1\(\alpha\)-hydroxylase results in the hormonally active form of vitamin D\(_3\), 1,25(OH)\(_2\)D\(_3\) \(^6\). Normal circulating levels of 1,25(OH)\(_2\)D\(_3\) in plasma is in the pico mole range and is \(\sim\)a 1000 fold lower than that of 25(OH)D3. The half life of 1,25(OH)\(_2\)D\(_3\) in circulation was determined to be between 4 and 6 hours \(^7\) while the half life of 25(OH)D3 is about 30 days \(^8\). 1,25(OH)\(_2\)D\(_3\) regulates its synthesis by inhibiting the production of renal 1\(\alpha\)-hydroxylase, as well as by inducing expression of an enzyme which initiates degradation and excretion of 1,25(OH)\(_2\)D\(_3\). The mechanism of synthesis and degradation of 1,25(OH)\(_2\)D\(_3\) is tightly regulated in order to maintain serum calcium levels within normal range. Abnormal increase in 1,25(OH)\(_2\)D\(_3\) may result in hypercalcemia which on its turn may cause a variety of symptoms ranging from dehydration and kidney stones to coma and death.

1,25(OH)\(_2\)D\(_3\) elicits antiproliferative effects in a variety of cancer cell types including cell lines derived from prostate \(^9,10\). The ability of 1,25(OH)\(_2\)D\(_3\) to inhibit prostate growth was also demonstrated in primary prostatic cells from histologically normal, benign prostatic hyperplasia (BPH), and prostate cancer specimens \(^11\), in multiple prostate cancer cell lines \(^12\)-\(^14\), in xenograft models of prostate cancer \(^15,16\) as well as in Dunning rat prostate model \(^17\). The anticancer mechanisms of 1,25(OH)\(_2\)D\(_3\)’s action include induction of cell cycle arrest, promotion of differentiation, inhibition of proliferation and angiogenesis, as well as inhibition of invasive and migratory potential of cancer cells [reviewed in \(^18\)].

Classical actions of 1,25(OH)\(_2\)D\(_3\) are mediated through the vitamin D receptor (VDR) which is a member of a superfamily of nuclear steroid hormone receptors. Upon 1,25(OH)\(_2\)D\(_3\) binding VDR
translocates to the nucleus, dimerizes with retinoid X receptor (RXR) and modulates the expression of target genes. Although a number of 1,25(OH)_{2}D_{3} responsive genes are known, the exact mechanism of growth regulation by 1,25(OH)_{2}D_{3} is not completely defined; however, an increase in p21 and/or p27 is an almost universal feature.

One of the central contributing factors which facilitates the survival of prostate cancer cells is attributed to the phosphoinositol-3 kinase PI3K-AKT pathway. Activated AKT phosphorylates a host of proteins that affect cell growth, cell cycle entry, and cell survival. The AKT pathway presents an attractive target for anticancer therapies and several AKT inhibitors have been developed that demonstrate anticancer activity in preclinical and clinical studies. In prostate cancer, activation of AKT occurs most frequently due to the loss of tumor suppressor phosphatase and a tensin homologue deleted in chromosome ten (PTEN). Loss of PTEN protein occurs in 20% of primary prostate tumors and this loss is highly correlated with advanced tumor grade and stage with 50% of metastatic tumors exhibiting a loss of PTEN protein. Moreover, loss of heterozygosity (LOH) is found in 20% to 60% of metastatic tumors. Data suggests that advancing disease is associated with a progressive loss of PTEN or an accumulation of mutations in the PTEN gene. Loss of PTEN and activation of AKT has been shown to downregulate the expression of p21 and p27 by a number of mechanisms.

In our preliminary data we had shown that Pten WT mouse prostatic epithelial cells (MPEC) exhibit significant levels of growth-inhibition in response to the presence of 1,25(OH)_{2}D_{3}, whereas growth of Pten-/- MPECs in which Pten was lost in vivo are not affected by 1,25(OH)_{2}D_{3}. Pretreatment of Pten-/- MPECs with PI3K/AKT inhibitors resulted in the partial restoration of sensitivity to 1,25(OH)_{2}D_{3}. Given our preliminary findings and the existing data contained within recent literature, we proposed the hypothesis that 1,25(OH)_{2}D_{3}-mediated growth inhibition of prostate epithelial cells is antagonized by PTEN loss.
Body

As it was described in the previous (2008-2009) Annual Report we evaluated the role of Pten in responsiveness to 1,25(OH)_{2}D_{3} using shRNA knockdown and by in vitro knockout of Pten. We demonstrated that MPEC that lost Pten expression remained sensitive to the antiproliferative action of 1,25(OH)_{2}D_{3}. These data demonstrate that while in vivo loss of Pten was associated with resistance to 1,25(OH)_{2}D_{3}-mediated growth inhibition of MPEC as demonstrated by our preliminary data, in vitro suppression or loss of Pten in MPECs was not associated with increased resistance to 1,25(OH)_{2}D_{3}. Thus our initial hypothesis that Pten loss antagonizes 1,25(OH)_{2}D_{3}-mediated growth inhibition of prostate epithelial cells was not confirmed.

Interestingly, we found that pharmacological inhibitors of PI3K or Akt and 1,25(OH)_{2}D_{3} synergistically inhibited growth of DU145, LNCaP, primary human prostate cancer cell strains and Pten null mouse prostatic epithelial cells (MPEC). The inhibitors used included API-2 (Triciribine) and GSK690693 which are currently in clinical trials for treatment of cancer. A novel mechanism for antiproliferative effects of 1,25(OH)_{2}D_{3} in prostate cells, induction of senescence, was discovered. Combination of 1,25(OH)_{2}D_{3} and AKT inhibitor cooperated to induce G_{1} arrest and senescence. These findings provided the rationale for prostate cancer therapies involving use of AKT inhibitors and 1,25(OH)_{2}D_{3} in adjunctive therapy.

2009-2010 Progress

Part I. In 2009-2010 we further developed the study described in the 2008-2009 Annual Report. The results are summarized in a manuscript that is now accepted for publication in Prostate and currently is in press (the manuscript is attached).

In brief, we sought to evaluate the effect of AKT inhibition and 1,25(OH)_{2}D_{3} treatment on protein levels of p21^{Cip1} and p27^{Kip1} role since the antiproliferative effects of 1,25(OH)_{2}D_{3} are known to commonly involve upregulation of p21^{Cip1} and/or p27^{Kip1}. Our results demonstrated that treatment with API-2 and 1,25(OH)_{2}D_{3} cooperated to increase p21^{Cip1} protein (Fig. 3F of the attached manuscript). These data suggest that synergism between API-2 and 1,25(OH)_{2}D_{3} in prostate cancer cells might be a result of cooperative induction of cell cycle arrest and senescence possibly through induction of p21^{Cip1} levels.

We also evaluated the effect of Pten status on the presence of synergism between 1,25(OH)_{2}D_{3} and AKT inhibitor API-2. WFU3 Control shRNA MPEC (the clone with the lowest levels of phosphor-
Ser473 Akt) and WFU3 Pten shRNA MPEC (the clone with the highest levels of phospho- Ser473 Akt and phosphor-Thr308 Akt) were treated with 1,25(OH)2D3, API-2 or with multiple combinations of the two compounds. Out of all dose combinations tested the control clone MPEC showed “intermediate” synergism at 10nM 1,25(OH)2D3 combined with 50nM or 100nM API-2 (Fig.5A, Table III of the attached manuscript). On the other hand, MPEC with Pten knock down showed “very strong” to “strong” synergism throughout all tested dose combinations of 1,25(OH)2D3 and API-2 as determined by the CI values (Fig. 5B, Table III of the attached manuscript). A similar trend was observed in the MPEC with Pten deleted using Cre-recombinase. Briefly, Pten^lox/lox MPEC demonstrated only “intermediate” synergism between 1,25(OH)2D3 and API-2 at 10nM 1,25(OH)2D3 combined with 5nM and 50nM API-2, while the Pten^-/- MPEC demonstrated “strong” to “very strong” synergism at the highest dose of API-2 tested (500nM) combined with any dose of 1,25(OH)2D3 (data not shown).

Together, data demonstrated that suppression or loss of Pten in MPECs was not associated with increased resistance to growth-inhibitory qualities of 1,25(OH)2D3 in MPEC. In addition, our data suggests that loss of Pten might strengthen the synergistic effect between 1,25(OH)2D3 and AKT inhibition on cellular growth inhibition.

In conclusion, these findings provide the rationale for the development of therapies utilizing 1,25(OH)2D3 or its analogs combined with inhibition of PI3K/AKT for the treatment of prostate cancer.

**Part II: Growth inhibition of prostate cancer cells by 1,25(OH)2D3: role of senescence.**

The mechanism of growth inhibition mediated by 1,25(OH)2D3 in prostate cells is not completely elucidated. Our finding showed that 1,25(OH)2D3 was able to induce senescence in prostate cells. The ability of 1,25(OH)2D3 to induce senescence has not been demonstrated before and contributes to the understanding of the antiproliferative effects of 1,25(OH)2D3 in prostate cells. Thus, we further evaluate the ability of 1,25(OH)2D3 to induce senescence in prostate cells as well as study mechanism of this induction.

Senescent cells are described as a cell permanently arrested in the cell cycle. These cells are refractory to proliferation stimuli, exhibit altered cell morphology and gene expression while remaining viable and preserving metabolic activity (reviewed in 31). There are multiple data demonstrating that senescence is a mechanism that limits cellular lifespan and presents a barrier for cellular immortalization and progression of tumorigenesis 32, 33. DNA damage or oncogene expression can induce cellular senescence and in order to become immortal cells have to overcome senescence by acquiring additional genetic alterations.
A process of senescence was demonstrated to have a significant role in human cancers as well. It was shown that human benign tumors contain senescent cells and that these cells disappear in their malignant counterparts \(^{34,35}\). In human prostate cancer Majumder et al. \(^{36}\) demonstrated that markers of cellular senescence are elevated in PIN when compared to nondysplastic epithelial cells in the same tissue section. Chen et al. \(^{37}\) showed that in specimens from early-stage human prostate cancer markers of senescence were present in areas of prostate hyperplasia/PIN and rarely in areas of carcinoma. These findings suggest a role for senescence as a barrier for progression of tumorigenesis in prostatic cells. The ability of 1,25(OH)\(_2\)D\(_3\) to induce senescence in human primary prostate cancer cell strain demonstrated in the study supports utilization of 1,25(OH)\(_2\)D\(_3\) for the treatment of earlier stages of human prostate cancer with the goal of prevention of disease progression.

In spite of strong proliferative effects on prostatic cells, treatment of prostate cancer with 1,25(OH)\(_2\)D\(_3\) is limited due to the calcium mobilizing effects of high dose 1,25(OH)\(_2\)D\(_3\) \(^{38,39}\). In 1998, Schwartz et al. showed that human primary prostatic epithelial cells (HPEC) express 1\(\alpha\)-hydroxylase and can convert 25(OH)D\(_3\) to 1,25(OH)\(_2\)D\(_3\) \(^{40}\). In addition, we have previously observed that 25(OH)D\(_3\) induced strong antiproliferative effects in HPEC (unpublished data). Moreover, recent data demonstrated that prostate cells express 25(OH)-hydroxylase \(^{41}\) suggesting that 1,25(OH)\(_2\)D\(_3\) can be synthesized in prostate cells in autocrine manner from cholecalciferol (cholecalciferol to 25(OH)D\(_3\) to 1,25(OH)\(_2\)D\(_3\)). Thus, in addition to testing role of 1,25(OH)\(_2\)D\(_3\) on induction of senescence in prostate cells, we are also interested in testing the ability of cholecalciferol and 25(OH)D\(_3\) to induce senescence in human prostatic epithelial cells.

We have isolated normal, BPH as well as cancer human primary cell strains as previously described \(^{42}\). Two cell strains of normal, BPH, and cancer human primary cells are used in the experiments. We are assessing growth inhibition (by trypan blue viability assay) and senescence (\(\beta\)-galactosidase activity) upon treatment with increasing doses of 1,25(OH)\(_2\)D\(_3\), 25(OH)D\(_3\) and cholecalciferol. We also isolate RNA and proteins at various time points upon treatment.

Our preliminary data is demonstrated below in the Figures P-1 through P-4. We observed that 27% of the WFU55 (normal human prostate epithelial cell strain) cells were undergoing senescence after treatment with 100 nM 1,25(OH)\(_2\)D\(_3\) (Figure P-1). The results obtained using other cell strains as well as results from experiments utilizing cholecalciferol and 25(OH)D\(_3\) are being analyzed.

In addition to human primary cell strains we confirmed ability of 1,25(OH)\(_2\)D\(_3\) to induce senescence in mouse prostatic progenitor cells that have been isolated in our lab \(^{43}\). Over 40% of the WFU3 clone 3 prostatic progenitor MPEC were positive for the senescence-associated \(\beta\)-galactosidase activity (Figure P-2).
We further sought to evaluate the role of Pten in the ability of 1,25(OH)₂D₃ to induce senescence. Thus, we treated Pten flox/flox MPEC as well as Pten-/- MPEC with increasing concentrations of 1,25(OH)₂D₃ and assessed induction of senescence by senescence-associated β-galactosidase activity. Our preliminary data suggests presence of more pronounced senescence in cells that have lost Pten expression as well as increased ability of 1,25(OH)₂D₃ to induce senescence in the cells lacking Pten. Quantification of this data is in progress (Figure P-3). Similar results were observed in MPEC where Pten was knocked down using shRNA approached (as described in the Materials and Methods section of the attached manuscript) (Figure P-4).

Next, we would like to evaluate the role of p21 and p27 in the induction of senescence in prostate cells by 1,25(OH)₂D₃. To do so, we designed shRNA sequences and have generated a lentivirus that we will use to infect the human primary prostate epithelial cells. We hypothesize that p21 and/or p27 is critical for the induction of senescence in prostatic cells.
**Figure P-1:** Growth inhibition and induction on senescence in human primary prostate epithelial cell strain WFU55 upon treatment with increasing concentration of 1,25(OH)₂D₃.

**P-1A.** Representative photographs of senescence induction in WFU55 human primary epithelial prostate cells treated with increasing concentrations of 1,25(OH)₂D₃ as determined by senescence-associated β-galactosidase activity. Cells treated with Doxorubicin were used as a positive control. For negative control senescence was assessed at pH 7 in Doxorubicin-treated cells.

![Representative photographs of senescence induction in WFU55 human primary epithelial prostate cells](image)

**P-1B.** Growth inhibition of WFU55 human primary epithelial prostate cell strain treated with increasing concentration of 1,25(OH)₂D₃ as determined by trypan blue viability assay.

![Growth inhibition of WFU55 human primary epithelial prostate cell strain treated with increasing concentration of 1,25(OH)₂D₃ as determined by trypan blue viability assay](image)

**P-1C.** Quantification of senescence evaluation of WFU55 human primary epithelial prostate cells treated with increasing concentrations of 1,25(OH)₂D₃ as determined by senescence-associated β-galactosidase activity.

![Quantification of senescence evaluation of WFU55 human primary epithelial prostate cells treated with increasing concentrations of 1,25(OH)₂D₃ as determined by senescence-associated β-galactosidase activity](image)
Figure P-2. Induction of senescence in WFU3 clone 3 mouse prostatic epithelial cells as determined by senescence-associated β-galactosidase activity.
**Figure P-3.** Pten flox/flox MPEC and Pten-/- counterparts were treated with increasing concentrations of 1,25(OH)$_2$D$_3$ and induction of senescence was determined by assessment of senescence-associated β-galactosidase activity. Cells treated with Doxorubicin were used as a positive control, while assessment of senescence at pH 7 in cells treated with Doxorubicin were used as a negative control.

![Pten floxed MPEC](image1)

![Pten -/-, Cre MPEC](image2)

**Figure P-4.** MPEC WFU3 Control shRNA clone and respective WFU3 Pten shRNA clone were treated with increasing concentrations of 1,25(OH)$_2$D$_3$ and induction of senescence was determined by assessment of senescence-associated β-galactosidase activity. Cells treated with Doxorubicin were used as a positive control, while assessment of senescence at pH 7 in cells treated with Doxorubicin were used as a negative control.

![Control shRNA Clone](image3)

![Pten shRNA Clone](image4)
**Key research accomplishments**

- Manuscript is accepted for publication in Prostate journal (in press).
- Confirmed presence of synergism between AKT inhibitor API-2 and 1,25(OH)$_2$D$_3$ in cells expressing Pten as well as cells that have lost Pten.
- Demonstrated cooperative induction of p21 by AKT inhibitor API-2 and 1,25(OH)$_2$D$_3$ which might play role in cooperative induction of senescence by the two compounds.
- Have designed shRNA sequences targeting p21 and p27 in human cells and generated lentivirus that will allow knock down on the p21 and p27 protein in human cells.
- Preliminary data further confirms role of senescence in anti-proliferative qualities of 1,25(OH)$_2$D$_3$.

**Reportable outcomes**

Altogether, we have demonstrated that pharmacological inhibitors of PI3K or Akt restored sensitivity to antiproliferative effects of 1,25(OH)$_2$D$_3$ in 1,25(OH)$_2$D$_3$-insensitive cells and synergized to inhibit the growth of Pten-/- mouse prostatic epithelial cells, DU145, LNCaP and primary human prostate cancer cell strains. The inhibitors used included API-2 (Triciribine) and GSK690693 which are currently in clinical trials for treatment of cancer. The combination of 1,25(OH)$_2$D$_3$ and AKT inhibitor API-2 led to a cooperative increase in G$_1$ arrest and in the induction of senescence. AKT is commonly activated by PTEN loss, therefore we evaluated the role of Pten in responsiveness to 1,25(OH)$_2$D$_3$ using shRNA knockdown and by *in vitro* knockout of Pten. We found that Pten status did not affect responsiveness to the antiproliferative action of 1,25(OH)$_2$D$_3$.

In the past year we further developed the study and have demonstrated that in DU145 cells API-2 and 1,25(OH)$_2$D$_3$ cooperated to induce p21 expression which may be associated with induction of senescence. In addition, we showed presence of this synergism in cells expressing Pten and in cells that have lost Pten. We found more pronounced synergism in cells with lower Pten expression (attached manuscript, Figure 6 and Table III).

Presently, we are working on confirmation of the ability of 1,25(OH)$_2$D$_3$ (as well as 25(OH)D$_3$ and cholecalciferol) to induce senescence in prostate cells and determination of the mechanism of this senescence. We are evaluating the role of Pten, p21, p27 for the induction of senescence by 1,25(OH)$_2$D$_3$ (and potentially by 25(OH)D$_3$ and cholecalciferol).
Conclusions

Altogether, we demonstrate that Pten status *per se* did not affect responsiveness to the antiproliferative action of 1,25(OH)$_2$D$_3$. We discovered that pharmacological inhibitors of PI3K or AKT are capable of restoring sensitivity to antiproliferative effects of 1,25(OH)$_2$D$_3$ in 1,25(OH)$_2$D$_3$-insensitive cells. In addition, the PI3K/AKT inhibitors tested synergized to inhibit the growth of Pten-/− mouse prostatic epithelial cells, DU145, LNCaP and primary human prostate cancer cell strains. Combination of 1,25(OH)$_2$D$_3$ and AKT inhibitor cooperated to induce G1 arrest, senescence, and p21 levels in prostate cancer cells.

As AKT is commonly activated by PTEN loss, we evaluated the role of Pten in responsiveness to 1,25(OH)$_2$D$_3$ using shRNA knockdown and by *in vitro* knockout of Pten. MPEC that lost Pten expression remained sensitive to the antiproliferative action of 1,25(OH)$_2$D$_3$, and showed higher degree of synergism between AKT inhibitor and 1,25(OH)$_2$D$_3$ compared to Pten-expressing counterparts.

Inhibitors of the PI3K/AKT pathway included Triciribine and GSK690693 which are currently in clinical trials for treatment of cancer and the effect of the combination was 10 to 1000 times greater than the AKT inhibitor alone as was demonstrated by Dose Reduction Indexes. This synergistic effect has not been previously demonstrated and could significantly enhance the therapeutic efficacy of these clinically relevant drugs while reducing the potential side effects. Thus, these findings provide the rationale for the development of therapeutic interventions utilizing 1,25(OH)$_2$D$_3$ or its analogs combined with inhibition of PI3K/AKT for the treatment of prostate cancer.
References:


ARTICLE PUBLISHED IN PROSTATE JOURNAL

1,25-dihydroxyvitamin D₃ and PI3K/AKT inhibitors synergistically inhibit growth and induce senescence in prostate cancer cells

Linara S. Axanova¹, Yong Q. Chen¹, Thomas McCoy², Guangchao Sui¹ and Scott D. Cramer¹,².

¹Cancer Biology and ²Public Health Science Departments, Wake Forest University School of Medicine, Medical Center Blvd., Winston Salem, NC 27157, U.S.A..

Correspondence to: Scott D. Cramer, Department of Cancer Biology, Wake Forest University School of Medicine, Medical Center Blvd. Winston-Salem, NC 27157, U.S.A. scramer@wfubmc.edu

Key Words: Vitamin D₃, AKT, prostate, cancer, synergism

Running Title: Vitamin D₃ and AKT in prostate
Abstract: BACKGROUND: 1-alpha, 25-dihydroxy vitamin D₃ (1,25(OH)₂D₃) inhibits proliferation of multiple cancer cell types including prostate cells and upregulates p21 and/or p27, while loss of Pten and PI3K/AKT activation stimulates survival and downregulates p21 and p27. We hypothesized that inhibition of the PI3K/AKT pathway synergizes with the antiproliferative signaling of 1,25(OH)₂D₃.

METHODS: Viability, cell cycle and senescence of cells were evaluated upon combinational treatment with 1,25(OH)₂D₃ and pharmacological PI3K/AKT inhibitors. RESULTS: Pharmacological inhibitors of PI3K or Akt and 1,25(OH)₂D₃ synergistically inhibited growth of DU145, LNCaP, primary human prostate cancer cell strains and Pten null mouse prostatic epithelial cells (MPEC). The inhibitors used included API-2 (Triciribine) and GSK690693 which are currently in clinical trials for treatment of cancer. A novel mechanism for antiproliferative effects of 1,25(OH)₂D₃ in prostate cells, induction of senescence, was discovered. Combination of 1,25(OH)₂D₃ and AKT inhibitor cooperated to induce G₁ arrest, senescence, and p21 levels in prostate cancer cells. As AKT is commonly activated by PTEN loss, we evaluated the role of Pten in responsiveness to 1,25(OH)₂D₃ using shRNA knockdown and by in vitro knockout of Pten. MPEC that lost Pten expression remained sensitive to the antiproliferative action of 1,25(OH)₂D₃, and showed higher degree of synergy between AKT inhibitor and 1,25(OH)₂D₃ compared to Pten-expressing counterparts. CONCLUSIONS: These findings provide the rationale for the development of therapies utilizing 1,25(OH)₂D₃ or its analogs combined with inhibition of PI3K/AKT for the treatment of prostate cancer.
Introduction

Prostate cancer is the most commonly diagnosed cancer and the second most common cause of cancer death in American men (1). Vitamin D deficiency has been associated with the development of clinical prostate cancer (2, 3).

Vitamin D is a hormone that can be obtained from the diet or produced endogenously by a series of reactions that culminate in the most active metabolite of vitamin D, 1α, 25(OH)2-vitamin D3 (1,25(OH)2D3). 1,25(OH)2D3 elicits antiproliferative effects in a variety of cancer cell types including cell lines derived from prostate (4, 5). The ability of 1,25(OH)2D3 to inhibit prostate growth was also demonstrated in primary prostatic cells from histologically normal, benign prostatic hyperplasia, and prostate cancer specimens, in multiple prostate cancer cell lines (7-9), in xenograft models of prostate cancer (10, 11) as well as in Dunning rat prostate model (12). The anticancer mechanisms of 1,25(OH)2D3’s action include induction of cell cycle arrest, promotion of differentiation, inhibition of proliferation and angiogenesis, as well as inhibition of invasive and migratory potential of cancer cells (reviewed in 13).

Classical actions of 1,25(OH)2D3 are mediated through the vitamin D receptor (VDR) which is a member of a superfamily of nuclear steroid hormone receptors. Upon 1,25(OH)2D3 binding VDR translocates to the nucleus, dimerizes with retinoid X receptor (RXR) and modulates the expression of target genes. Although a number of 1,25(OH)2D3 responsive genes are known, the exact mechanism of growth regulation by 1,25(OH)2D3 is not completely defined; however, an increase in p21 and/or p27 is an almost universal feature (4).

One of the central contributing factors which facilitates the survival of prostate cancer cells is attributed to the phosphoinositol-3 kinase PI3K-AKT pathway. Activated AKT phosphorylates a host of proteins that affect cell growth, cell cycle entry, and cell survival. The AKT pathway presents an attractive target for anticancer therapies and several AKT inhibitors have been developed that demonstrate anticancer activity in preclinical and clinical studies (14). In prostate cancer, activation of AKT occurs most frequently due to the loss of tumor suppressor phosphatase and a tensin homologue deleted in chromosome ten (PTEN) (15-17). Loss of PTEN protein occurs in 20% of primary prostate tumors and this loss is highly correlated with advanced tumor grade and stage with 50% of metastatic tumors exhibiting a loss of PTEN protein (18). Moreover, loss of heterozygosity (LOH) is found in 20%
to 60% of metastatic tumors (19). Data suggests that advancing disease is associated with a progressive loss of PTEN or an accumulation of mutations in the PTEN gene. Loss of PTEN and activation of AKT has been shown to downregulate the expression of p21 and p27 by a number of mechanisms (20-24). Since the antiproliferative effects of 1,25(OH)₂D₃ involve upregulation of p21 and/or p27 4 while activation of PI3K/AKT downregulates their expression (24), we hypothesized that pharmacological inhibitors of AKT will cooperate with the antiproliferative actions of 1,25(OH)₂D₃ in prostate cancer cells.

Our results demonstrate that inhibition of PI3K or AKT synergized with 1,25(OH)₂D₃ to inhibit the growth of human prostate cancer cell lines and primary human prostate cancer strains, and led to the cooperative induction of G₁ arrest and senescence. Responsiveness to the antiproliferative effects of 1,25(OH)₂D₃ was not lost upon reduction of Pten expression or its deletion. We observed a higher susceptibility to synergism between 1,25(OH)₂D₃ and AKT inhibitor in MPECs with lost Pten expression compared to the cells expressing Pten. These findings provide the rationale for prostate cancer therapies involving use of AKT inhibitors and 1,25(OH)₂D₃ in adjunctive therapy.
Materials and Methods

Materials. 1,25(OH)\textsubscript{2}D\textsubscript{3} (Biomol, Plymouth Meeting, PA) was reconstituted in 100% ethanol and stored at -80°C. LY294002 (Sigma-Aldrich Co., St Louis, MO), GSK690693 (26) (a generous gift from GlaxoSmithKline, Collegeville, PA) and API-2 (27) (Calbiochem, La Jolla, CA) were reconstituted in DMSO and stored at -20°C.

shRNA Infection. WFU3 MPEC (25) were infected with lentivirus expressing shRNA targeting Pten (gaa cct gat cat tat aga tat t) or control shRNA (gggc cat ggc acg tac ggc aag ). Lentivirus production and infection procedure were previously described (26). MPEC were clonally selected using serial dilution as described (27) and Pten status was confirmed by Immunoblot.

MPECs with acute deletion of Pten: Prostate-specific Pten-knockout mice were generated by crossing Pten\textsuperscript{loxP/loxP} mice (28) with mice of the ARR2Probasin-cre transgenic line PB-cre4, wherein the Cre recombinase is under the control of a modified rat prostate-specific probasin promoter (22), as previously reported (29). Pten\textsuperscript{lox/lox} anterior mouse prostatic epithelial cells (MPECs) were isolated from 8 week old Pten\textsuperscript{lox/lox; pbCre-} animals as described (25) and infected with self-deleting Cre-recombinase lentivirus (Pten\textsuperscript{-/-}) (30). Deletion was validated by PCR and Immunoblot.

Tissue culture. LNCaP and DU145 cells (both from American Type Culture Collection, Manassas, VA) were grown in RPMI-1640 supplemented with 10% FBS and 1% Penicillin-Streptomycin. MPEC were grown as described previously (25). Human prostate epithelial cancer cell strain WFU273Ca was isolated from fresh human prostate (prostate cancer, Gleason grade 6) validated for histological origin and maintained as previously described (31). Acquisition of the human specimen from radical prostatectomies was performed at Wake Forest University School of Medicine in compliance with Institutional Research Board approval. Briefly, a small piece of tissue was removed and minced. The tissue was digested with collagenase overnight. To remove the collagenase and the majority of the stromal cells, the tissue was rinsed and centrifuged. The tissue was inoculated into a tissue culture dish coated with collagen type I (Collagen Corporation, Palo Alto, CA) and grown in medium PFMR-4A (32) supplemented with growth factors and hormones as described (31). The histology of each specimen was verified by inking and fixing the prostate after dissection and serially sectioning the marked area as well as the sections immediately adjacent to the area of the dissection. The cells that grew out from the
tissue were aliquoted and stored in liquid nitrogen. The frozen aliquots were thawed to produce secondary cultures, which were grown in medium MCDB 105 (Sigma, St. Louis, MO) supplemented with growth factors and hormones as described (31).

**Growth assays for synergism determination.** Cells were plated at $10^4$ cells per 35 mm dish in triplicate. To determine synergism cells were treated with increasing doses of AKT inhibitor, increasing doses of $1,25(OH)_2D_3$ or multiple combinations of AKT inhibitor and $1,25(OH)_2D_3$. Briefly, 48 hr after plating the cell growth medium was replaced with 1 ml of experimental medium containing twice (2x) the indicated concentration of a PI3K/AKT inhibitor or vehicle (DMSO, 1x = 0.1% V/V). One hour later 1 ml of medium containing twice the final concentration of $1,25(OH)_2D_3$ or vehicle (ethanol, 1x = 0.1% V/V) was added to each dish. An AKT inhibitor was applied 1 hour prior to the $1,25(OH)_2D_3$ treatment as API-2 was shown to reduce phosphorylation of AKT and phosphorylation of AKT’s downstream targets (Bad, AFX, and GSK-3β) as early as at 1 hour post treatment (33). In addition, our preliminary tests demonstrated that application of AKT inhibitor 1 hr prior to $1,25(OH)_2D_3$ treatment demonstrated moderately stronger synergism of growth inhibition compared to 0 hr, 4 hr, 8 hr and 24 hr between the treatments (data not shown).

DU145, LNCaP cells and MPEC remained in the experimental medium until the vehicle control cells reached 80-90% confluence, typically 5-7 days. For WFU273Ca and for all experiments using GSK690693 the experimental medium was replaced every 48hr. Viable cells were counted with a hemacytometer after trypan blue exclusion. Results of representative experiments are shown.

**Flow cytometry:** Flow cytometry was performed as described (5) using Becton Dickinson FACSCaliber and analyzed by the Cell Quest Pro v.6.0 program (Becton Dickinson, Mansfield, MA). Data were processed with ModFit LT v.2.0 software (Verity Software House, Topsham, MN). Each treatment was performed in triplicate and the experiment was conducted three times.

**Senescence-associated (SA)-β-galactosidase (gal) activity:** Cells were cultured and treated as described above. After 5-7 days of treatment (SA)-β-galactosidase activity was evaluated by the method of Dimri et al. (34). For positive control SA-β-gal activity was evaluated in cells treated with 100
nM Doxorubicin; for negative control SA-β-gal activity was evaluated in cells treated with 100 nM Doxorubicin at pH 7 which inhibits SA-β-gal activity. Digital images were taken from 10 random areas at 20X magnification. Digital images were evaluated in Photoshop CS2 9.0.2 (Adobe Systems, San Jose, CA). The number of SA-β-gal positive cells was counted in each image and presented as percent of total cell number ± SE.

**Immunoblot:** Cells were collected from monolayer by light trypsinization and cell pellets were resuspended in lysis buffer (20 mM HEPES, 10 mM NaCl, 3 mM MgCl₂, 0.1% NP40, 10% glycerol, 0.2 mM EDTA) containing freshly added 1 mM DTT and 0.4 mM PMSF. Tubes with cells were left on ice for 15 min. 50 μg of protein were subjected to electrophoresis on SDS-PAGE gels. Proteins were transferred onto prewetted Hybond-P PVDF (polyvinylidene difluoride) membrane according to manufactures' protocol (Amersham Pharmacia Biotech, Buckinghamshire, UK). Membranes were incubated with appropriate dilutions of Pten (sc-7974) (Santa Cruz Biotechnology, Santa Cruz, CA), p21 (556430) and p27 (610241) antibodies (BD Pharmigen, San Diego, CA). Secondary antibodies conjugated to horse radish peroxidase (Santa Cruz Biotechnology) were used. ECL Plus Western Blotting Detection System kit (Amersham-Pharmacia) was used for detection of proteins. Images were analyzed by ImageQuant TL v. 7.0 (GE Healthcare, Piscataway, NJ).

**Detection of phosphorylated proteins:** Cells were grown to approximately 80% confluency, medium was replaced with fresh medium, and in 24 hr protein lysates were prepared. Cells were washed with cold PBS and lysis buffer (1% NP-40, 50 mM Tris-Hcl, 150 mM NaCl, 5 mM EDTA with freshly added protease inhibitor cocktail, 100 mM DTT, 100 mM Na₃VO₄ and 500 mM NaF) was applied. Cells were left on ice for 20 min, collected, and centrifuged. Supernatants were stored at -80°C. 30-50 μg of protein were subjected to electrophoresis on SDS-PAGE gels. Proteins were transferred onto Nitrocellulose membrane (Bio-Rad Laboratories, Hercules, CA) according to the manufacturer’s protocols. Membranes were incubated with appropriate dilutions of pSer473 AKT (#4051), pThr308 AKT (#2965), AKT (#9272) antibodies (Cell Signaling Inc., Beverly, MA). Secondary antibodies conjugated to horse radish peroxidase (Santa Cruz Biotechnology) were used. Protein expression
levels were detected using ECL Plus Western Blotting Detection System kit (Amersham-Pharmacia). Images were analyzed by ImageQuant TL v. 7.0 (GE Healthcare, Piscataway, NJ).

**Statistical Analyses:** Synergism was assessed with CalcuSyn software (Biosoft, Ferguson, MO) as previously described (5). Briefly, the dose effect for each drug alone was determined based on the experimental observations using the median effect principle: the combination index (CI) for each combination was calculated according to the following equation: 

\[
CI = \frac{(D_1)(D_2)}{(D_{x1})(D_{x2})} + \frac{(D_1)}{(D_{x1})} + \frac{(D_2)}{(D_{x2})},
\]

where \((D_1)\) and \((D_2)\) are the doses of drug that have \(x\) effect when used in combination and \((D_{x1})\) and \((D_{x2})\) are the doses of drug 1 and drug 2 that have the same \(x\) effect when used alone. \(CI = 1\) represents the conservation isobologram and indicates additive effects. \(CI\) values < 1 indicate a more than expected additive effect (synergism). Dose Reduction Index (DRI) for each drug and dose was calculated using the equation: 

\[
(DRI)_1 = \frac{(D_{x1})}{(D_1)} \quad \text{and} \quad (DRI)_2 = \frac{(D_{x2})}{(D_2)}.
\]

Statistical analyses for synergism experiments were performed using the statistical software package NCSS 2002 (Number Cruncher Statistical Systems, Kaysville, UT). Differences in growth data were determined by two-way ANOVA controlling for 1,25(OH)\(_2\)D\(_3\) or PI3K/AKT inhibitor dose with post hoc analysis by Fisher’s test. Cell cycle distribution and senescence analyses were performed using two-way ANOVA with post hoc analysis by Fisher’s LSD test. In all cases, \(P\leq0.05\) was considered significant. The effect of 1,25(OH)\(_2\)D\(_3\)-mediated growth inhibition in MPECs with Pten shRNA and scrambled control or Pten\(^{-/-}\) and Pten\(^{lox/lox}\) was evaluated using two-way ANOVA while adjusting for the within-clone correlation using a random effect in a corresponding mixed-effects model. Data were analyzed in PROC MIXED in SAS v9.2.
Results

1,25(OH)₂D₃ and PI3K/Akt inhibitors synergistically inhibit prostate cancer cell growth.

To test whether inhibition of the PI3K/Akt pathway synergizes with 1,25(OH)₂D₃ treatment to inhibit the growth of prostatic cells we first utilized a pharmacological inhibitor of PI3K/AKT, LY294002 (35). Cells were treated with increasing doses of 1,25(OH)₂D₃ or LY294002 or with multiple combinations of the two compounds and the number of viable cells was assessed. This was followed by assessment of synergism using the Chou-Talalay method (36) in which the combination index (CI) values < 1 indicates presence of synergism.

We found that LNCaP cells, which lack functional PTEN and are moderately sensitive to growth inhibition by 1,25(OH)₂D₃, demonstrated statistically significant synergism between 1,25(OH)₂D₃ and LY294002 at lower doses of 1,25(OH)₂D₃ (Fig. 1A, Table I). The combination of 1 nM 1,25(OH)₂D₃ treatment with 0.2 μM, 1 μM or 5 μM LY294002 demonstrated statistically significant synergism as determined by CI values from isobologram analysis (Table I). The dose-reduction index (DRI) for each of the drugs is also depicted in Table I and presents a predictive measure of how much the dose of each drug in a synergistic combination may be reduced at a given effect level compared with the doses of each drug alone (36).

DU145 cells (wild-type PTEN) are known to be resistant to the antiproliferative effects of 1,25(OH)₂D₃ (37). Consistent with this, we found that 1,25(OH)₂D₃ did not significantly affect growth of DU145 cells (Fig. 1B). While 100 nM 1,25(OH)₂D₃ did not inhibit growth of DU145 cells, pretreatment of DU145 cells with 5 μM LY294002 sensitized the cells to 1,25(OH)₂D₃ treatment leading to a reduction in the number of viable cells to 40% compared to treatment with LY294002 alone (Fig.1B). Significant synergism was observed across multiple doses of both compounds (Table I).

As LY294002 has recently been reported to have many other off-target effects (38), we sought to validate synergism with AKT-inhibition specifically. To do so we used two different AKT inhibitors which currently are in clinical trials for cancer treatment: API-2 (Triciribine), which selectively inhibits Akt1/2/3 without inhibiting PI3K or PDK (33) and GSK690693, an ATP competitive AKT inhibitor (39).
The combination of 1,25(OH)2D3 with API-2 elicited synergistic growth inhibition of DU145 cells (Fig. 2A, Table II). DU145 cells treated with the combination of API-2 and 1,25(OH)2D3 demonstrated strong synergism at all doses tested as determined by CI values from isolobolgrams (Table II). Noteworthy, the treatment with API-2 and 1,25(OH)2D3 was applied only once after which the cells were allowed to grow until the cells in either of the treatment groups were 80-90% confluent.

Next we tested for the presence of synergism in primary human prostate cancer epithelial cells. WFU273Ca human primary epithelial cell strain was isolated from fresh human prostate with histologically confirmed prostate cancer of Gleason grade 6. The strain was shown to be PTEN-positive by Immunoblot, while still demonstrating high levels of activated phosphorylated AKT (Fig. 2B, insert). The combination of API-2 and 1,25(OH)2D3 applied to WFU273Ca strain also demonstrated statistically significant synergism (Fig. 2B, Table II), with DRI values as high as 15.3 for 1,25(OH)2D3 and 14.6 for API-2.

Even though both cell types, the WFU273Ca cell strain and DU145 cell line, are PTEN-positive, WFU273Ca shows activation of AKT pathway as demonstrated by phospho-AKT levels (Fig.2B, insert) while DU145 consistently demonstrated undetectable levels of pAKT (data not show). The mechanistic basis for activated AKT in WFU273Ca is not known. The higher sensitivity of the WFU273Ca cell line to growth inhibition by AKT inhibitor API-2 might be explained by possible dependency of WFU273Ca on AKT activation for proliferation of the cells.

The combination of GSK690693 with 1,25(OH)2D3 also elicited strong to very strong synergistic growth inhibition in DU145 cells (Fig. 2C, Table II), as well as moderate to very strong synergism in human primary prostatic epithelial cells (Fig. 2D, Table II).

1,25(OH)2D3 and PI3K/Akt inhibitors cooperate to inhibit cell cycle progression and induce senescence

Having demonstrated synergism between 1,25(OH)2D3 and AKT inhibitors we sought to explore the mechanism. First, we performed video time-lapse microscopy analysis of DU145 cells treated with API-
2 (0.25 μM) or 1,25(OH)₂D₃ (100 nM) alone as well as in combination of the two. We did not observe any considerable apoptosis in either of the treatments (data not shown). Next we evaluated cell cycle distribution of DU145 cells treated with API-2 or 1,25(OH)₂D₃. Cell cycle analysis demonstrated a small but statistically significant increase in G₁-arrested cells treated with the combination of API-2 at 0.25 μM with 1,25(OH)₂D₃ at 10 nM compared to either agent alone (Fig. 3).

When we assessed the effects of drug combination on senescence in the human primary prostate cancer cell strain WFU273Ca, we found that 1,25(OH)₂D₃ was able to induce SA-β-Gal activity which was associated with morphological features consistent with senescence (Fig. 4A, B). Interestingly, inhibition of the AKT pathway with API-2 alone induced senescence in WFU273Ca cells with 0.5μM API-2 causing 30% of the cells to undergo senescence, suggesting a role for activated AKT in the prevention of senescence in these cells (Fig. 3C). The combination of API-2 and 1,25(OH)₂D₃ cooperated to induce greater SA-β-Gal activity which was statistically significant by ANOVA (Fig. 3D). Treatment with 0.1 μM API-2 induced senescence in 6.5% of WFU273Ca cells and 10 nM 1,25(OH)₂D₃ induced senescence in 7.3% of the cells; while the combination of the two led to 24.0% of the cells to undergo senescence (Fig. 3D). DU145 cells also showed cooperativity for induction of SA-β-gal (Fig. 3E).

As the antiproliferative effects of 1,25(OH)₂D₃ commonly involve upregulation of p21Cip₁ and/or p27Kip₁ (4) we sought to test the effect of AKT inhibition and 1,25(OH)₂D₃ treatment on protein levels of p21Cip₁ and p27Kip₁ in DU145. The result demonstrated that 24hr of treatment with API-2 and 1,25(OH)₂D₃ cooperated to increase p21Cip₁ protein (Fig. 3F). While 0.25μM API-2 treatment increased p21 by 3.7 fold and 100nM 1,25(OH)₂D₃ did not have a significant effect, the combination of the two led to an 8.3 fold increase in the p21Cip₁ protein level compared to the base level. Although API-2 treatment modestly increased p27 levels, 1,25(OH)₂D₃, alone or in combination with API-2 did not demonstrate a significant effect on p27 protein levels.

Together these data suggest that synergism between API-2 and 1,25(OH)₂D₃ in prostate cancer cells might be a result of cooperative induction of cell cycle arrest and senescence possibly through induction of p21Cip₁ levels.
The role of Pten status in sensitivity to antiproliferative action of 1,25(OH)₂D₃.

Activation of AKT in prostate cancer occurs most frequently due to the loss of the tumor suppressor phosphatase and a tensin homologue deleted in chromosome ten (PTEN), which is found in 20% of primary tumors and more than 50% of metastatic tumors (18). Thus, we wanted to evaluate the role of Pten in the antiproliferative signaling of 1,25(OH)₂D₃. To test this we generated MPEC in which Pten expression was suppressed using an shRNA approach. MPEC WFU3 (25) were infected with either lentivirus expressing scrambled shRNA or with lentivirus expressing shRNA targeting Pten. Single cell clones of each of the cell types were established and Pten status was verified by Immunoblot (Fig.5B). All clones with Pten expression knocked down to undetectable levels were selected and activation of Akt pathway was confirmed by assessment of Akt phosphorylation. Clones infected with Pten shRNA activated Akt pathways as phospho-Ser473 and phospho-Thr308 Akt levels were increased compared to the Control clones (Fig.5B).

WFU3 control MPEC clones and WFU3 MPEC clones with Pten knocked down were treated with increasing doses of 1,25(OH)₂D₃ (Fig.5A). Both cell types exhibited robust growth suppression by 1,25(OH)₂D₃ in a dose-dependant manner. There was a trend towards increased sensitivity of Pten shRNA clones to 1,25(OH)₂D₃-mediated growth inhibition at 10nM dose (p=0.041) but not at 100nM (p=0.655) as shown by two-way ANOVA. The overall test for any differences (across Ethanol, 10nM, 100nM) in Control and Pten shRNA clones was not significant (p=0.089). These findings demonstrate that loss of Pten expression and activation of Akt pathway doesn’t reduce responsiveness of the cells to the antiproliferative effects of 1,25(OH)₂D₃ and suggests a possible increase in the sensitivity of the cells with lost Pten to the antiproliferative actions of 1,25(OH)₂D₃.

Since gene suppression using an shRNA approach has the potential disadvantages of incomplete suppression of target gene expression and also possible off-target effects, we sought to establish a cell line with acute in vitro deletion of Pten. Thus, we isolated Pten<sup>lox/lox</sup> MPEC from prostates of Pten<sup>lox/lox</sup> Cre-recombinase negative animals and infected them with lentivirus expressing self-deleting Cre-recombinase (30). PCR analysis (data not shown) and Immunoblot analysis (Fig. 5D) demonstrated the absence of Pten expression in the cells infected with Cre-recombinase. Deletion of Pten led to 5.6 fold increase in phosphor-Ser473 Akt level confirming activation of the Akt pathway (Fig. 5D). The control
Pten\textsubscript{lox/lox} MPEC and Pten\textsuperscript{−/−} (Pten\textsubscript{lox/lox} infected with Cre-recombinase lentivirus) cells were treated with increasing concentrations of 1,25(OH)\textsubscript{2}D\textsubscript{3}. We observed that \textit{in vitro} loss of Pten did not significantly affect the ability of 1,25(OH)\textsubscript{2}D\textsubscript{3} to inhibit the growth of the cells (Fig. 5B).

Pten\textsubscript{lox/lox} MPEC demonstrated higher sensitivity to 1,25(OH)\textsubscript{2}D\textsubscript{3} compared to WFU3 MPEC used for the shRNA knock down of Pten. This could be attributed to the difference in the genetic background of the mouse strains from which the cell lines were established. The WFU3 MPECs used for the infection with shRNA-expressing virus were isolated from prostates of B1/6; 129/SVEV mice (25), while Pten\textsubscript{lox/lox} MPEC were isolated from mice of mixed C57BL/6 and BALB/c background (40, 29).

We also evaluated the effect of Pten status on the presence of synergism between 1,25(OH)\textsubscript{2}D\textsubscript{3} and AKT inhibitor API-2. WFU3 Control clone 3 MPEC (the clone with the lowest levels of phosphor-Ser473 Akt) and WFU3 Pten shRNA clone 4 MPEC (the clone with the highest levels of phosphor-Ser473 Akt and phosphor-Thr308 Akt) were treated with 1,25(OH)\textsubscript{2}D\textsubscript{3} (0.1nM, 1nM, 10nM, and 100nM) or API-2 (10nM, 50nM, 100nM, and 500n) or with multiple combinations of the two compounds. Out of all dose combinations tested the control clone MPEC showed “intermediate” synergism at 10nM 1,25(OH)\textsubscript{2}D\textsubscript{3} combined with 50nM or 100nM API-2 (Fig.5A, Table III). On the other hand, MPEC with Pten knock down showed “very strong” to “strong” synergism throughout all tested dose combinations of 1,25(OH)\textsubscript{2}D\textsubscript{3} and API-2 as determined by the CI values (Fig. 5B, Table III). A similar trend was observed in the MPEC with Pten deleted using Cre-recombinase. Briefly, Pten\textsubscript{lox/lox} MPEC demonstrated only “intermediate” synergism between 1,25(OH)\textsubscript{2}D\textsubscript{3} and API-2 at 10nM 1,25(OH)\textsubscript{2}D\textsubscript{3} combined with 5nM and 50nM API-2, while the Pten\textsuperscript{−/−} MPEC demonstrated “strong” to “very strong” synergism at the highest dose of API-2 tested (500nM) combined with any dose of 1,25(OH)\textsubscript{2}D\textsubscript{3} (data not shown).

Together, these data demonstrate that suppression or loss of Pten in MPECs was not associated with increased resistance to growth-inhibitory qualities of 1,25(OH)\textsubscript{2}D\textsubscript{3} in MPEC. In addition, our data suggests that loss of Pten might strengthen the synergistic effect between 1,25(OH)\textsubscript{2}D\textsubscript{3} and AKT inhibition on cellular growth inhibition.
Discussion

In this study we showed that AKT inhibitors in combination with 1,25(OH)₂D₃ synergistically inhibit the growth of prostate cancer cells. The effect was observed with multiple inhibitors of PI3K and/or AKT in MPEC with Pten knock down, prostate cancer cell lines, as well as primary human prostate cancer sample.

These findings might be important as AKT inhibitors (including the ones tested in this study) are in clinical trials for various cancers (14,26,50), and therefore the results could have fast clinical translation. However, a factor complicating the use of AKT inhibitors is that the AKT pathway presents one of the most important pathways for normal cell survival. It is not clear yet whether treatment with AKT inhibitors will demonstrate acceptable levels of toxicity at doses that are therapeutically effective.

1,25(OH)₂D₃ used as a single agent has been shown to possess anticancer qualities in a number of cancer models but has toxicities associated with calcium mobilization at doses that are therapeutically effective (4). One strategy to overcome this problem is the creation of less calcemic 1,25(OH)₂D₃ analogs or organization of the treatment regimen in a way that allows reduction of side-effects. Another strategy is to combine 1,25(OH)₂D₃ with other agents to develop therapeutic interventions that allow dose reduction, and thus alleviation of toxicities, while maintaining the growth inhibitory potential. Clinical trials utilizing 1,25(OH)₂D₃ or its analogs in combination with chemotherapy in advanced prostate cancer have demonstrated the feasibility of the use of 1,25(OH)₂D₃ for treatment of advanced prostate cancer (51-53). For instance, Beer et al. reported an 81% response rate for the combination of 1,25(OH)₂D₃ and docetaxel in metastatic prostate cancer versus an expected response of 40% to 50% for docetaxel alone (41).

In this light, synergism between 1,25(OH)₂D₃ with AKT inhibitors and DRI values demonstrated in this study suggests that more therapeutic efficacy can be achieved by combining AKT inhibitors and 1,25(OH)₂D₃ (or its analogs) potentially reducing systemic toxicities.

Mechanistically, combinational treatment with AKT inhibitor and 1,25(OH)₂D₃ showed no evidence of apoptosis, but moderate effect on cell cycle progression and larger effect on the induction of senescence was observed.
Treatment with 1,25(OH)\textsubscript{2}D\textsubscript{3} alone did not have an effect on senescence in DU145 cells which is in agreement with the observation that these cells are not growth-inhibited by 1,25(OH)\textsubscript{2}D\textsubscript{3}. However, combined with AKT inhibitor API-2, 1,25(OH)\textsubscript{2}D\textsubscript{3}, increased the percentage of cells undergoing senescence.

In human primary prostate cancer cell strain treatment with 1,25(OH)\textsubscript{2}D\textsubscript{3} alone was able to inhibit proliferation of the cells as well as to induce senescence as demonstrated by induction of β-galactosidase staining and senescence-associated cell morphology alterations. The ability of 1,25(OH)\textsubscript{2}D\textsubscript{3} to induce senescence in prostate cells has not been demonstrated before and contributes to the understanding of the antiproliferative effects of 1,25(OH)\textsubscript{2}D\textsubscript{3} in prostate cells which have not been clearly defined.

Senescent cells are described as a cell permanently arrested in the cell cycle. These cells are refractory to proliferation stimuli, exhibit altered cell morphology and gene expression while remaining viable and preserving metabolic activity (reviewed in ((42). There are multiple data demonstrating that senescence is a mechanism that limits cellular lifespan and presents a barrier for cellular immortalization and progression of tumorigenesis (43, 44). DNA damage or oncogene expression can induce cellular senescence and in order to become immortal cells have to overcome senescence by acquiring additional genetic alterations.

A process of senescence was demonstrated to have a significant role in human cancers as well. It was shown that human benign tumors contain senescent cells and that these cells disappear in their malignant counterparts (45, 46). In human prostate cancer Majumder et al. (47) demonstrated that markers of cellular senescence are elevated in PIN when compared to nondysplastic epithelial cells in the same tissue section. Chen et al. (48) showed that in specimens from early-stage human prostate cancer markers of senescence were present in areas of prostate hyperplasia/PIN and rarely in areas of carcinoma. These findings suggest a role for senescence as a barrier for progression of tumorigenesis in prostatic cells. The ability of 1,25(OH)\textsubscript{2}D\textsubscript{3} to induce senescence in human primary prostate cancer cell strain demonstrated in the study supports utilization of 1,25(OH)\textsubscript{2}D\textsubscript{3} for the treatment of earlier stages of human prostate cancer with the goal of prevention of disease progression. Ultimately, combination of 1,25(OH)\textsubscript{2}D\textsubscript{3} with pharmacological AKT inhibitors might provide further benefits by stimulation of senescence, reduction of growth of cancer cell and blocking or slowing tumorigenesis.
It was previously demonstrated that p21 or p27 expression plays a critical role in the induction of senescence in a number of cell types (49-51) including prostate cells (47). In addition, 1,25(OH)_2D_3 has been shown to increase the steady-state levels of p27 protein in prostate cancer cells (52). Thus, we sought to explore the effect of AKT inhibition and 1,25(OH)_2D_3 treatment on the p21 and p27 levels. In agreement with the lack of response to antiproliferative action of 1,25(OH)_2D_3 DU145 that did not induce p21, p27 levels upon 1,25(OH)_2D_3 treatment. However, when AKT inhibitor API-2 induced p21 protein levels, the cooperative induction of p21 by the combinational treatment with API-2 and 1,25(OH)_2D_3 was observed, which correlated with sensitization of the cells to the antiproliferative effects of 1,25(OH)_2D_3 and induction of senescence. Thus, while 1,25(OH)_2D_3-sensitive cell strains undergo senescence upon 1,25(OH)_2D_3 treatment, the 1,25(OH)_2D_3-insensitive DU145 cell line required an AKT inhibitor treatment in order for 1,25(OH)_2D_3 to inhibit proliferation and induce senescence.

As activation of AKT in prostate cancer commonly occurs due to the loss of expression of functional PTEN (18), we evaluated the role of Pten in responsiveness to 1,25(OH)_2D_3, as well as the role of Pten in synergistic cell growth inhibition upon treatment with 1,25(OH)_2D_3 in combination with AKT inhibitors.

We demonstrated that loss of Pten in MPEC was not associated with decreased responsiveness of the cells to antiproliferative effects of 1,25(OH)_2D_3. There was a suggestion for increased sensitivity of cells with deleted Pten to lower dose of 1,25(OH)_2D_3 tested (10nM) as shown by slightly higher growth inhibition of MPEC clones with Pten knocked down using shRNA compared to the Control MPEC clones at that dose (p=0.041).

More profound synergism between 1,25(OH)_2D_3 and AKT inhibitor API-2 was observed in MPEC that lost Pten expression as compared to the Pten-expressing counterparts. This finding, if confirmed by further studies, could be relevant to clinical application as cancer cells with lost Pten would be more sensitive to the growth-inhibitory effects of the combinational treatment leading to more selective growth inhibition of prostate cancer cells. However, in human prostate cancer cell lines synergism was observed in cells with functional Pten (DU145), as well as in cells lacking Pten activity (LNCaP). Thus, role of Pten status for the induction of synergism might be cell-type specific.
Conclusions

In summary, our results show that 1,25(OH)₂D₃ and AKT inhibitors synergistically inhibit prostate cancer growth through induction of cell cycle and senescence. We also have demonstrated that reduced Pten expression was not associated with decreased response to antiproliferative actions of 1,25(OH)₂D₃ suggesting that 1,25(OH)₂D₃ can be used for treatment independent of PTEN status of the tumor. These data may have implications for the clinical use of these agents in prostate cancer patients especially in patient with high risk for progression.

Acknowledgement

We are grateful to GlaxoSmithKline (Collegeville, PA) which generously provided GSK690693 used in the study. We thank Dr. George Kulik (Department of Cancer Biology, Wake Forest University School of Medicine) for providing us with API-2. Authors declare to have no financial or personal relationship which may inappropriately influence the presentation of this work.
Figure Legends

Figure 1. LY294002 and 1,25(OH)₂D₃ synergistically inhibits growth of LNCaP and DU145 cells. Growth inhibition of LNCaP(A) and DU145(B) in response to LY294002 and 1,25(OH)₂D₃ alone or in combination. Cells were grown, treated and analyzed as described in Materials and Methods. Each point represents the mean and standard deviation of triplicate plates after normalization of cell number to controls (0.1% ethanol).

Figure 2. AKT inhibitors API-2 and GSK690693 synergize with 1,25(OH)₂D₃ to inhibit growth of DU145 cells and human primary prostate cancer strain. Growth inhibition of DU145 cells (A) and human primary prostate cancer cell strain WFU273Ca (B) in response to API-2 and 1,25(OH)₂D₃ alone or in combination. Growth inhibition of DU145 cells in response to GSK690693 and 1,25(OH)₂D₃ alone or in combination (C). Insert demonstrates PTEN and phospho-AKT levels in WFU273Ca cell strain as determined by Immunoblot. Growth inhibition of human primary prostate cancer cell strain WFU273Ca in response to GSK690693 and 1,25(OH)₂D₃ alone or in combination (D). Cells were grown, treated and analyzed as described in Materials and Methods.

Figure 3. AKT inhibitor API-2 and 1,25(OH)₂D₃ cooperate to induce G1-arrest in DU145 cells. DU145 cells were treated with the indicated doses for 24 hr and evaluated for cell cycle distribution as described in the Materials and Methods section. Insert demonstrates the G1/S ratios. Values are means for the triplicates ± SD. Means without a common letter are significantly different by ANOVA (P < 0.05).

Figure 4. AKT inhibitor API-2 and 1,25(OH)₂D₃ cooperate to induce G1 senescence and p21 levels. (A) Representative photographs of 1,25(OH)₂D₃ and API-2 inducing (SA)-β-galactosidase activity in a cooperative manner in WFU273Ca cells. (B,C,D) Quantitative data from multiple images of WFU273Ca cells treated as indicated. Analysis was performed as described in the Materials and Methods section. Means ± SE are shown. Means without a common letter are significantly different by ANOVA (P < 0.05). (F) Induction of senescence by 1,25(OH)₂D₃ alone or in presence of 0.25 µM API-2.
in DU145 cells. Quantitative data from ten images of DU145 cells treated as indicated. Cells were
grown, treated and (SA)-β-galactosidase activity was evaluated as described in Materials and Methods.
Means ± SE are shown. Means without a common letter are significantly different by ANOVA (P <
0.05). (E) API-2 and 1,25(OH)\_2D\_3 cooperatively induce p21 and p27 protein levels in DU145 cells.
DU145 cells were treated with vehicle, 0.25µM API-2 or 100 nM 1,25(OH)\_2D\_3 or the combination of the
two and in 24hr protein lysates were collected and Immunoblot was carried out as described in
Materials and Methods.

**Figure 5. In vitro suppression or loss of Pten is not sufficient to antagonize 1,25(OH)\_2D\_3-
mediated growth suppression.** (A) Growth inhibition of WFU3 MPECs infected with Pten shRNA or
scrambled shRNA in response to 1,25(OH)\_2D\_3. Values are means for the triplicates ±SD. (B) Pten and
phospho-Akt levels of WFU3 MPEC clones infected with lentivirus expressing scrambled shRNA
(control clones) or shRNA targeting Pten (Pten shRNA clones) as determined by Immunoblot. (C)
Growth inhibition of Pten\textsuperscript{lox/lox} and Pten\textsuperscript{-/-} MPECs in response to 1,25(OH)\_2D\_3. Pten\textsuperscript{lox/lox} MPECs isolated
from prostates of Pten\textsuperscript{lox/lox} Cre-recombinase negative animals and infected with lentivirus expressing
self-deleting Cre-recombinase to generate Pten\textsuperscript{-/-} MPEC. Values are means for the triplicates ±SD. (D)
Pten and phospho-Akt levels of Pten\textsuperscript{lox/lox} and Pten\textsuperscript{-/-} MPECs determined by Immunoblot. Protein lysate
isolated from LNCaP cells was used as controls.

**Figure 6. AKT inhibitor API-2 synergizes with 1,25(OH)\_2D\_3 to inhibit growth of MPEC with
reduced or lost Pten expression.** Growth inhibition of Control shRNA clone 3 MPEC (A), Pten shRNA
clone 4 (B) in response to API-2 and 1,25(OH)\_2D\_3 alone or in combination. MPEC were established,
grown, treated and analyzed as described in Materials and Methods.
References


Figure 5

A

Viability of Cells, Normalized

- Control, clone 3
- Control, clone 4
- Control, clone 5
- Pten shRNA, clone 4
- Pten shRNA, clone 5
- Pten shRNA, clone 6
- Pten shRNA, clone 8
- Pten shRNA, clone 11

Control

p = 0.09

Ethanol
10nM
1,25(OH)₂D₃
100nM

B

<table>
<thead>
<tr>
<th>Scrambled shRNA</th>
<th>Pten shRNA</th>
</tr>
</thead>
<tbody>
<tr>
<td>cl.3</td>
<td>cl.4</td>
</tr>
<tr>
<td>2.0</td>
<td>1.5</td>
</tr>
<tr>
<td>Pten</td>
<td>0.3</td>
</tr>
<tr>
<td>p473 AKT</td>
<td>1.1</td>
</tr>
<tr>
<td>p308 AKT</td>
<td>1.2</td>
</tr>
<tr>
<td>Actin</td>
<td></td>
</tr>
</tbody>
</table>

C

Viability of Cells, Normalized

- Pten lox/lox
- Pten -/-

p = 0.290

Ethanol
1nM
10nM
100nM

1,25(OH)₂D₃

D

<table>
<thead>
<tr>
<th>LNCaP Pten&lt;sup&gt;lox/lox&lt;/sup&gt;</th>
<th>Pten&lt;sup&gt;-/-&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pten</td>
<td>0.0</td>
</tr>
<tr>
<td>p473 AKT</td>
<td>15.2</td>
</tr>
<tr>
<td>p308 AKT</td>
<td>2.5</td>
</tr>
<tr>
<td>Actin</td>
<td></td>
</tr>
</tbody>
</table>
Figure 6

A  Control shRNA clone 3 MPEC

B  Pten shRNA clone 4 MPEC
Table I. Synergism between 1,25(OH)2D3 and LY294002 in LNCaP and DU145 cells***

<table>
<thead>
<tr>
<th></th>
<th>1,25(OH)2D3, nM</th>
<th>LY294002, μM</th>
<th>CI*</th>
<th>DRI** 1,25(OH)2D3</th>
<th>LY294002</th>
<th>Synergism</th>
</tr>
</thead>
<tbody>
<tr>
<td>LNCaP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>0.2</td>
<td>0.171</td>
<td>8.2</td>
<td>20.7</td>
<td></td>
<td>Strong</td>
</tr>
<tr>
<td>1</td>
<td>1</td>
<td>0.298</td>
<td>10.9</td>
<td>4.8</td>
<td></td>
<td>Strong</td>
</tr>
<tr>
<td>1</td>
<td>0.5</td>
<td>0.675</td>
<td>26.3</td>
<td>1.6</td>
<td></td>
<td>Moderate</td>
</tr>
<tr>
<td>DU145</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>2.5</td>
<td>0.408</td>
<td>513.8</td>
<td>2.5</td>
<td></td>
<td>Intermediate</td>
</tr>
<tr>
<td>1</td>
<td>5</td>
<td>0.650</td>
<td>666.0</td>
<td>1.5</td>
<td></td>
<td>Intermediate</td>
</tr>
<tr>
<td>10</td>
<td>2.5</td>
<td>0.382</td>
<td>58.2</td>
<td>2.8</td>
<td></td>
<td>Intermediate</td>
</tr>
<tr>
<td>10</td>
<td>5</td>
<td>0.654</td>
<td>67.7</td>
<td>1.6</td>
<td></td>
<td>Intermediate</td>
</tr>
<tr>
<td>10</td>
<td>10</td>
<td>0.801</td>
<td>117.6</td>
<td>1.3</td>
<td></td>
<td>Moderate</td>
</tr>
<tr>
<td>100</td>
<td>2.5</td>
<td>0.489</td>
<td>6.4</td>
<td>3.0</td>
<td></td>
<td>Intermediate</td>
</tr>
<tr>
<td>100</td>
<td>5</td>
<td>0.585</td>
<td>9.5</td>
<td>2.1</td>
<td></td>
<td>Intermediate</td>
</tr>
<tr>
<td>100</td>
<td>10</td>
<td>0.701</td>
<td>14.9</td>
<td>1.6</td>
<td></td>
<td>Intermediate</td>
</tr>
</tbody>
</table>

*Combination Index (CI<0.1 indicates Very Strong Synergism; 0.1÷0.3 Strong Synergism; 0.3÷0.7 Synergism; 0.70÷0.85 Moderate Synergism; 0.85÷0.90 Slight Synergism; 0.90÷1.10 Nearly Additive Synergism).

**Dose-reduction Index. DRI is calculated using the equation: (DRI)_1=(D_x)_1/D_1 and (DRI)_2=(D_x)_2/D_2, where (D)_1 and (D)_2 are the doses of drug that have x effect when used in combination and (D_x)_1 and (D_x)_2 are the doses of drug 1 and drug 2 that have the same x effect when used alone.

*** Data are from assays depicted in Figure 1, only statistically significantly different means by ANOVA are depicted.
<table>
<thead>
<tr>
<th>1,25(OH)2D3, nM</th>
<th>AKT inhibitor, nM</th>
<th>CI*</th>
<th>1,25(OH)2D3</th>
<th>AKT Inhibitor</th>
<th>Synergism</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DU145</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AKT Inhibitor: API-2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.1</td>
<td>50</td>
<td>0.18*10^-6</td>
<td>5.5*10^4</td>
<td>4.0*10^6</td>
<td>Very Strong</td>
</tr>
<tr>
<td>0.1</td>
<td>100</td>
<td>0.12*10^-6</td>
<td>8.7*10^4</td>
<td>4.4*10^6</td>
<td>Very Strong</td>
</tr>
<tr>
<td>0.1</td>
<td>500</td>
<td>7.98*10^-6</td>
<td>1.3*10^5</td>
<td>1.9*10^6</td>
<td>Very Strong</td>
</tr>
<tr>
<td>0.1</td>
<td>1000</td>
<td>9.82*10^-6</td>
<td>1.2*10^5</td>
<td>7.4*10^5</td>
<td>Very Strong</td>
</tr>
<tr>
<td>1</td>
<td>50</td>
<td>0.75*10^-6</td>
<td>1.3*10^4</td>
<td>1.8*10^7</td>
<td>Very Strong</td>
</tr>
<tr>
<td>1</td>
<td>100</td>
<td>0.55*10^-6</td>
<td>1.8*10^4</td>
<td>1.6*10^7</td>
<td>Very Strong</td>
</tr>
<tr>
<td>1</td>
<td>500</td>
<td>0.60*10^-6</td>
<td>1.7*10^4</td>
<td>2.7*10^6</td>
<td>Very Strong</td>
</tr>
<tr>
<td>1</td>
<td>1000</td>
<td>0.54*10^-6</td>
<td>1.9*10^4</td>
<td>1.6*10^6</td>
<td>Very Strong</td>
</tr>
<tr>
<td>10</td>
<td>50</td>
<td>0.001</td>
<td>872.1</td>
<td>8.8*10^6</td>
<td>Very Strong</td>
</tr>
<tr>
<td>10</td>
<td>100</td>
<td>0.001</td>
<td>1014.8</td>
<td>5.7*10^6</td>
<td>Very Strong</td>
</tr>
<tr>
<td>10</td>
<td>500</td>
<td>0.001</td>
<td>1950.4</td>
<td>3.5*10^6</td>
<td>Very Strong</td>
</tr>
<tr>
<td>10</td>
<td>1000</td>
<td>0.001</td>
<td>1461.5</td>
<td>1.1*10^6</td>
<td>Very Strong</td>
</tr>
<tr>
<td>100</td>
<td>50</td>
<td>0.007</td>
<td>135.6</td>
<td>1.9*10^7</td>
<td>Very Strong</td>
</tr>
<tr>
<td>100</td>
<td>100</td>
<td>0.005</td>
<td>206.7</td>
<td>1.9*10^7</td>
<td>Very Strong</td>
</tr>
<tr>
<td>100</td>
<td>500</td>
<td>0.006</td>
<td>180.3</td>
<td>3.1*10^6</td>
<td>Very Strong</td>
</tr>
<tr>
<td>100</td>
<td>1000</td>
<td>0.005</td>
<td>193.0</td>
<td>1.7*10^6</td>
<td>Very Strong</td>
</tr>
<tr>
<td><strong>WFU275CA</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AKT Inhibitor: API-2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.1</td>
<td>0.1</td>
<td>0.799</td>
<td>283.0</td>
<td>1.3</td>
<td>Moderate</td>
</tr>
<tr>
<td>1</td>
<td>0.05</td>
<td>0.720</td>
<td>12.2</td>
<td>1.6</td>
<td>Moderate</td>
</tr>
<tr>
<td>1</td>
<td>0.1</td>
<td>0.714</td>
<td>36.9</td>
<td>1.5</td>
<td>Moderate</td>
</tr>
<tr>
<td>10</td>
<td>0.025</td>
<td>0.216</td>
<td>9.0</td>
<td>9.6</td>
<td>Strong</td>
</tr>
<tr>
<td>10</td>
<td>0.05</td>
<td>0.169</td>
<td>22.5</td>
<td>8.0</td>
<td>Strong</td>
</tr>
<tr>
<td>10</td>
<td>0.1</td>
<td>0.176</td>
<td>52.0</td>
<td>6.4</td>
<td>Strong</td>
</tr>
<tr>
<td><strong>DU145</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AKT Inhibitor: GSK690693</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>1</td>
<td>0.003</td>
<td>1.1*10^6</td>
<td>391.3</td>
<td>Very Strong</td>
</tr>
<tr>
<td>10</td>
<td>10</td>
<td>0.070</td>
<td>6.5*10^4</td>
<td>14.3</td>
<td>Very Strong</td>
</tr>
<tr>
<td>100</td>
<td>0.1</td>
<td>0.0001</td>
<td>2.3*10^4</td>
<td>2241.4</td>
<td>Very Strong</td>
</tr>
<tr>
<td>100</td>
<td>1</td>
<td>0.004</td>
<td>3.9*10^4</td>
<td>268.7</td>
<td>Very Strong</td>
</tr>
<tr>
<td>100</td>
<td>10</td>
<td>0.010</td>
<td>1.5*10^6</td>
<td>96.9</td>
<td>Very Strong</td>
</tr>
<tr>
<td>100</td>
<td>100</td>
<td>0.061</td>
<td>6.6*10^6</td>
<td>16.3</td>
<td>Very Strong</td>
</tr>
<tr>
<td>100</td>
<td>1000</td>
<td>0.281</td>
<td>6.0*10^7</td>
<td>3.5</td>
<td>Strong</td>
</tr>
<tr>
<td><strong>WFU273CA</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AKT Inhibitor: GSK690693</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.1</td>
<td>1000</td>
<td>0.773</td>
<td>5158.7</td>
<td>1.3</td>
<td>Moderate</td>
</tr>
<tr>
<td>1</td>
<td>10</td>
<td>0.062</td>
<td>37.1</td>
<td>28.5</td>
<td>Very Strong</td>
</tr>
<tr>
<td>1</td>
<td>100</td>
<td>0.120</td>
<td>255.9</td>
<td>8.7</td>
<td>Strong</td>
</tr>
<tr>
<td>10</td>
<td>1000</td>
<td>0.747</td>
<td>550.1</td>
<td>1.3</td>
<td>Moderate</td>
</tr>
<tr>
<td>10</td>
<td>10</td>
<td>0.115</td>
<td>10.5</td>
<td>51.7</td>
<td>Strong</td>
</tr>
<tr>
<td>10</td>
<td>100</td>
<td>0.234</td>
<td>14.1</td>
<td>6.1</td>
<td>Strong</td>
</tr>
<tr>
<td>10</td>
<td>1000</td>
<td>0.344</td>
<td>215.4</td>
<td>3.0</td>
<td>Intermediate</td>
</tr>
</tbody>
</table>

*Combination Index (CI<0.1 indicates Very Strong Synergism; 0.1÷0.3 Strong Synergism; 0.3÷0.7 Synergism; 0.70÷0.85 Moderate Synergism; 0.85÷0.90 Slight Synergism; 0.90÷1.10 Nearly Additive Synergism)

**Dose-reduction Index. DRI is calculated using the equation: (DRI)=((Dx)1/D1) and (DRI)=((Dx)2/D2), where (D1) and (D2) are the doses of drug that have x effect when used in combination and (Dx)1 and (Dx)2 are the doses of drug 1 and drug 2 that have the same x effect when used alone. DRI values for 1,25(OH)2D3 treatment in DU145 are high due to inability of the program to correctly calculate DRI based on the formula as the x effect of the 1,25(OH)2D3 alone is near zero.

*** Data are from assays depicted in Figure 2, only statistically significantly different means by ANOVA are depicted.
### Table III. Synergism between 1,25(OH)2D3 and API-2 in MPEC***

<table>
<thead>
<tr>
<th>Control shRNA cl. 3 MPEC</th>
<th>1,25(OH)2D3, nM</th>
<th>LY294002, μM</th>
<th>CI* 1,25(OH)2D3</th>
<th>CI* API-2</th>
<th>DRI** 1,25(OH)2D3</th>
<th>DRI** API-2</th>
<th>Synergism</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>50</td>
<td></td>
<td>0.370</td>
<td>4.7</td>
<td>6.3</td>
<td>Intermediate</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>100</td>
<td></td>
<td>0.334</td>
<td>13.8</td>
<td>5.5</td>
<td>Intermediate</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pten shRNA cl. 4 MPEC</th>
<th>1,25(OH)2D3, nM</th>
<th>LY294002, μM</th>
<th>CI* 1,25(OH)2D3</th>
<th>CI* API-2</th>
<th>DRI** 1,25(OH)2D3</th>
<th>DRI** API-2</th>
<th>Synergism</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.1</td>
<td>500</td>
<td></td>
<td>0.018</td>
<td>57.2</td>
<td>9354.0</td>
<td>Very Strong</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>50</td>
<td></td>
<td>0.112</td>
<td>8.9</td>
<td>4121.8</td>
<td>Strong</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>100</td>
<td></td>
<td>0.099</td>
<td>10.1</td>
<td>2257.8</td>
<td>Very Strong</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>500</td>
<td></td>
<td>0.013</td>
<td>81.9</td>
<td>2122.8</td>
<td>Very Strong</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>10</td>
<td></td>
<td>0.217</td>
<td>4.6</td>
<td>6.9*10^4</td>
<td>Strong</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>50</td>
<td></td>
<td>0.134</td>
<td>7.5</td>
<td>2.0*10^4</td>
<td>Strong</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>100</td>
<td></td>
<td>0.095</td>
<td>10.5</td>
<td>1.3*10^4</td>
<td>Very Strong</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>500</td>
<td></td>
<td>0.013</td>
<td>78.8</td>
<td>1.1*10^4</td>
<td>Very Strong</td>
<td></td>
</tr>
<tr>
<td>100</td>
<td>10</td>
<td></td>
<td>0.246</td>
<td>4.1</td>
<td>3.5*10^5</td>
<td>Strong</td>
<td></td>
</tr>
<tr>
<td>100</td>
<td>50</td>
<td></td>
<td>0.205</td>
<td>4.9</td>
<td>8.0*10^4</td>
<td>Strong</td>
<td></td>
</tr>
<tr>
<td>100</td>
<td>100</td>
<td></td>
<td>0.177</td>
<td>5.6</td>
<td>4.4*10^4</td>
<td>Strong</td>
<td></td>
</tr>
<tr>
<td>100</td>
<td>500</td>
<td></td>
<td>0.048</td>
<td>20.7</td>
<td>2.3*10^4</td>
<td>Very Strong</td>
<td></td>
</tr>
</tbody>
</table>

*Combination Index (CI<0.1 indicates Very Strong Synergism; 0.1÷0.3 Strong Synergism; 0.3÷0.7 Synergism; 0.70÷0.85 Moderate Synergism; 0.85÷0.90 Slight Synergism; 0.90÷1.10 Nearly Additive Synergism)

**Dose-response Index. DRI is calculated using the equation: \((DRI)_{1} = (D_{x})_{1}/D_{1}\) and \((DRI)_{2} = (D_{x})_{2}/D_{2}\), where \((D_{x})_{1}\) and \((D_{x})_{2}\) are the doses of drug that have \(x\) effect when used in combination and \((D_{x})_{1}\) and \((D_{x})_{2}\) are the doses of drug 1 and drug 2 that have the same \(x\) effect when used alone.

*** Data are from assays depicted in Figure 6, only statistically significantly different means by ANOVA are depicted.